Tirzepatide is often grouped with the GLP-1 drugs, but it is built differently, and that matters when you design a pharmacokinetic (PK) assay. It activates two receptors, GIP and GLP-1, from a single peptide. It travels bound to albumin. And its dose escalates across a six-fold range. Each of those facts changes what a good […]











